Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Crossref DOI link: https://doi.org/10.1186/s12944-017-0416-7
Published Online: 2017-01-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shah, Parth
Glueck, Charles J.
Goldenberg, Naila
Min, Sarah
Mahida, Chris
Schlam, Ilana
Rothschild, Matan
Huda, Ali
Wang, Ping
Funding for this research was provided by:
Jewish Hospital Lipoprotein Research Fund